Gastric retentive gabapentin dosage forms and methods for using same

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to treat a patient suffering from a pain state, wherein said medicament is to be administered to a patient in a twice-daily dosing regimen within a single 24 hour period.

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to reduce or eliminate side effects associated with γ-aminobutyric acid (GABA) analogs, wherein said medicament is to be administered to a patient in a once-daily dosing regimen within a single 24 hour period.

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to reduce or eliminate side effects associated with γ-aminobutyric acid (GABA) analogs, wherein said medicament is to be administered to a patient in a twice-daily dosing regimen within a single 24 hour period.

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to reduce or eliminate side effects associated with γ-aminobutyric acid (GABA) analogs, wherein said medicament is to be administered to a patient in a once-daily dosing regimen within a single 24 hour period or in a twice daily dosing regimen in which the dose in the morning and dose in the evening are not equal, also within a single 24 hour period, and wherein said medicament upon administration to a patient as a single dose results in blood plasma levels of the patient that exhibit a maximum concentration (Cmax) of gabapentin that is approximately 15% to approximately 85% less than Cmax for a comparable dose of immediate release gabapentin also administered as a single dose, and wherein upon administration, bioavailability (AUC from 0 to 24 hours at steady-state) of the gabapentin at 2400 mg is approximately 80% to approximately 150% of the AUC for a comparable total daily dose of immediate release gabapentin.

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to reduce or eliminate side effects associated with γ-aminobutyric acid (GABA) analogs, wherein said medicament is to be administered to a patient in a once-daily dosing regimen within a single 24 hour period or in a twice daily dosing regimen in which the dose in the morning and dose in the evening are not equal, also within a single 24 hour period, and wherein said medicament upon administration to a patient as a single dose results in blood plasma levels of the patient that exhibit a maximum concentration (Cmax) of gabapentin that is approximately 15% to approximately 85% less than Cmax for a comparable dose of immediate release gabapentin also administered as a single dose, and wherein upon administration, bioavailability (AUC from 0 to 24 hours at steady-state) of the gabapentin at 1800 mg is approximately 80% to approximately 150% of the AUC for a comparable total daily dose of immediate release gabapentin.

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to treat a patient suffering from a pain state, wherein said medicament is to be administered to a patient in a once-daily dosing regimen within a single 24 hour period or in a twice daily dosing regimen in which the dose in the morning and dose in the evening are not equal, also within a single 24 hour period, and wherein said medicament upon administration to a patient as a single dose results in blood plasma levels of the patient that exhibit a maximum concentration (Cmax) of gabapentin that is approximately 15% to approximately 85% less than Cmax for a comparable dose of immediate release gabapentin also administered as a single dose, and wherein upon administration, bioavailability (AUC from 0 to 24 hours at steady-state) of the gabapentin at 2400 mg is approximately 70% to approximately 150% of the AUC for a comparable total daily dose of immediate release gabapentin.

Use of a medicament comprising a therapeutically effective amount of a GABA analog in a gastric retentive dosage form to treat a patient suffering from a pain state, wherein said medicament is to be administered to a patient in a once-daily dosing regimen within a single 24 hour period or in a twice daily dosing regimen in which the dose in the morning and dose in the evening are not equal, also within a single 24 hour period, and wherein said medicament upon administration to a patient as a single dose results in blood plasma levels of the patient that exhibit a maximum concentration (Cmax) of gabapentin that is approximately 15% to approximately 85% less than Cmax for a comparable dose of immediate release gabapentin also administered as a single dose, and wherein upon administration, bioavailability (AUC from 0 to 24 hours at steady-state) of the gabapentin at 1800 mg is approximately 70% to approximately 150% of the AUC for a comparable total daily dose of immediate release gabapentin.